awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33387006-4D26FEE5-19A5-44C2-83F1-3206F444329C
Q33387006-4D26FEE5-19A5-44C2-83F1-3206F444329C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33387006-4D26FEE5-19A5-44C2-83F1-3206F444329C
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.
P2860
Q33387006-4D26FEE5-19A5-44C2-83F1-3206F444329C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33387006-4D26FEE5-19A5-44C2-83F1-3206F444329C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f9805830f14047ef604d7842e123e37b17faf080
P2860
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.